Mount Yale Investment Advisors LLC Cuts Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Mount Yale Investment Advisors LLC reduced its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 2.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,403 shares of the medical research company’s stock after selling 103 shares during the period. Mount Yale Investment Advisors LLC’s holdings in Charles River Laboratories International were worth $703,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in CRL. ProShare Advisors LLC grew its holdings in shares of Charles River Laboratories International by 6.2% during the 2nd quarter. ProShare Advisors LLC now owns 9,975 shares of the medical research company’s stock valued at $2,061,000 after purchasing an additional 583 shares during the last quarter. Kayne Anderson Rudnick Investment Management LLC boosted its position in Charles River Laboratories International by 1.7% during the second quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,908,989 shares of the medical research company’s stock valued at $394,359,000 after buying an additional 31,359 shares during the period. Sei Investments Co. grew its stake in shares of Charles River Laboratories International by 8.6% during the second quarter. Sei Investments Co. now owns 624,800 shares of the medical research company’s stock valued at $129,072,000 after buying an additional 49,451 shares during the last quarter. Canada Pension Plan Investment Board purchased a new position in shares of Charles River Laboratories International in the second quarter worth about $124,000. Finally, Public Employees Retirement Association of Colorado lifted its stake in shares of Charles River Laboratories International by 16.1% in the 2nd quarter. Public Employees Retirement Association of Colorado now owns 60,670 shares of the medical research company’s stock valued at $12,533,000 after acquiring an additional 8,415 shares during the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

CRL has been the topic of a number of analyst reports. Barclays decreased their price target on Charles River Laboratories International from $230.00 to $210.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 8th. JPMorgan Chase & Co. lowered shares of Charles River Laboratories International from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $270.00 to $205.00 in a report on Thursday, August 8th. The Goldman Sachs Group dropped their price target on shares of Charles River Laboratories International from $290.00 to $250.00 and set a “buy” rating for the company in a research report on Thursday, August 8th. Evercore ISI decreased their price objective on shares of Charles River Laboratories International from $265.00 to $225.00 and set an “outperform” rating on the stock in a research report on Thursday, August 8th. Finally, Robert W. Baird dropped their target price on shares of Charles River Laboratories International from $191.00 to $190.00 and set a “neutral” rating for the company in a report on Friday. Ten investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, Charles River Laboratories International presently has an average rating of “Hold” and an average target price of $227.55.

Charles River Laboratories International Price Performance

Shares of CRL stock opened at $203.83 on Tuesday. The business’s fifty day moving average is $209.09 and its 200 day moving average is $223.05. The company has a quick ratio of 1.21, a current ratio of 1.58 and a debt-to-equity ratio of 0.65. The stock has a market cap of $10.50 billion, a price-to-earnings ratio of 23.98, a PEG ratio of 3.89 and a beta of 1.36. Charles River Laboratories International, Inc. has a twelve month low of $161.65 and a twelve month high of $275.00.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, August 7th. The medical research company reported $2.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.39 by $0.41. Charles River Laboratories International had a net margin of 10.83% and a return on equity of 14.96%. The company had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.03 billion. Research analysts expect that Charles River Laboratories International, Inc. will post 10.01 EPS for the current fiscal year.

Charles River Laboratories International declared that its board has authorized a share buyback plan on Wednesday, August 7th that authorizes the company to buyback $1.00 billion in shares. This buyback authorization authorizes the medical research company to reacquire up to 9.6% of its shares through open market purchases. Shares buyback plans are generally an indication that the company’s leadership believes its shares are undervalued.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).